自2012年起，國外上市藥物早已不乏多種核醫診斷或核醫治療藥物，更顯見核醫放射藥物成長的潛力不容小覷。因此，除了目前有涵蓋於健保給付範圍之核醫診斷藥物FDG以外，研發新型核醫放射配體藥物之刻不容緩。 擁有多項製程/新藥專利的Primo專業團隊，不僅有豐富TFDA/CDE新藥臨床試驗的申請經驗，更已具備多種核醫放射藥物之開發經驗。
Since 2012, various types of radiodiagnostics or radiotherapeutics have appeared on the market and have shown great potential. The radiodiagnostics FDG is currently covered by many health insurance benefit packages, and the need for development of novel radioligand theranostics is urgent.
The professional and dedicated Primo team has been engaged in extensive clinical trials of new drugs for TFDA (Taiwan Food and Drug Administration) and CDE (Center for Drug Evaluation) as well as drug development experiences for radiopharmaceuticals. We are here to protect your health so that we may all enjoy a better tomorrow.
